Stock Chart

BBIO

$67.25 +0.51%
Score: 75.9 HOLD
LEAPs: SELL $100
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $100
Premium: $4.20
Expiry: Aug 20, 2027
Target: $100
Score: -91

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.90x (vs SPY: 0.9x | vs QQQ: 0.9x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Bear Pennant Bearish scenario quality 62/100
Setup invalidates on a close above $68.11 · pole −16% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About BBIO - BridgeBio Pharma, Inc. Common Stock

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Key Statistics

Market Cap $13B

This BBIO stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track BBIO's price movements with trendlines, gamma walls, and key support/resistance levels.